Perioperative PD-1 antibody tislelizumab plus chemotherapy for locally advanced gastro-oesophageal junction cancer: A prospective, nonrandomized, open-label, phase II trial

被引：0
|
作者：
Nie, Run-Cong
Ding, Ya
Yuan, Shu-Qiang
Li, Yuan-fang
Wang, Wei
Chen, Yongming
Cai, Muyan
Sun, Xiao-wei
Weng, Desheng
Li, Dandan
Zhao, Jingjing
Chen, Xiaojiang
Guan, Yuanxiang
Ma, Luo
Qiu, Haibo
Zhou, Zhi-wei
Zhang, Xiao-Shi
Chen, Ying-bo
机构：
[1] Sun Yat Sen Univ, Sun Yat sen Univ Canc Ctr, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou, Peoples R China
[2] Sun Yat Sen Univ, Ctr Canc, Biotherapy Ctr, Guangzhou, Peoples R China
[3] Sun Yat Sen Univ, Ctr Canc, Guangzhou, Peoples R China
[4] Sun Yat Sen Univ, Ctr Canc, Melanoma & Sarcoma Med Oncol Unit, Guangzhou, Peoples R China
[5] Sun Yat Sen Univ, Sun Ya Sen Univ Canc Ctr, Collaborat Innovat Ctr Canc Med, Ctr Canc, Guangzhou, Peoples R China
[6] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Ctr Canc, Guangzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4083
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Perioperative tislelizumab plus chemotherapy for locally advanced resectable thoracic esophageal squamous cell carcinoma trial: a prospective single-arm, phase II study (PILOT trial)
    Chengzhi Ding
    Yijun Guo
    Yaning zhou
    Yi He
    Chunji Chen
    Ming Zhang
    Xufeng Guo
    BMC Cancer, 23
  • [22] Perioperative chemotherapy with docetaxel plus oxaliplatin and S-1 (DOS) versus oxaliplatin plus S-1 (SOX) for the treatment of locally advanced gastric or gastro-esophageal junction adenocarcinoma (MATCH): an open-label, randomized, phase 2 clinical trial
    Zhichao Jiang
    Yibin Xie
    Wen Zhang
    Chunxia Du
    Yuxin Zhong
    Yuelu Zhu
    Liming Jiang
    Lizhou Dou
    Kang Shao
    Yongkun Sun
    Qi Xue
    Yantao Tian
    Shugeng Gao
    Dongbing Zhao
    Aiping Zhou
    Gastric Cancer, 2024, 27 : 571 - 579
  • [23] Perioperative chemotherapy with docetaxel plus oxaliplatin and S-1 (DOS) versus oxaliplatin plus S-1 (SOX) for the treatment of locally advanced gastric or gastro-esophageal junction adenocarcinoma (MATCH): an open-label, randomized, phase 2 clinical trial
    Jiang, Zhichao
    Xie, Yibin
    Zhang, Wen
    Du, Chunxia
    Zhong, Yuxin
    Zhu, Yuelu
    Jiang, Liming
    Dou, Lizhou
    Shao, Kang
    Sun, Yongkun
    Xue, Qi
    Tian, Yantao
    Gao, Shugeng
    Zhao, Dongbing
    Zhou, Aiping
    GASTRIC CANCER, 2024, 27 (03) : 571 - 579
  • [24] Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (TOGA): a phase 3, open-label, randomised controlled trial (vol 376, pg 687, 2010)
    Bang, Y-J
    Van Cutsem, E.
    Feyereislova, A.
    LANCET, 2010, 376 (9749): : 1302 - 1302
  • [25] PD-1 antibody (Camrelizumab) for metastatic EBV positive gastric cancer: A prospective single-arm, open-label, phase 2 trial.
    Qiu, Miaozhen
    Wang, De-Shen
    Sun, Yu-Ting
    Zhao, Qi
    Guan, Wen-Long
    Xu, Rui-hua
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [26] Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial
    Al-Batran, Salah-Eddin
    Homann, Nils
    Pauligk, Claudia
    Goetze, Thorsten O.
    Meiler, Johannes
    Kasper, Stefan
    Kopp, Hans-Georg
    Mayer, Frank
    Haag, Georg Martin
    Luley, Kim
    Lindig, Udo
    Schmiegel, Wolff
    Pohl, Michael
    Stoehlmacher, Jan
    Folprecht, Gunnar
    Probst, Stephan
    Prasnikar, Nicole
    Fischbach, Wolfgang
    Mahlberg, Rolf
    Trojan, Joerg
    Koenigsmann, Michael
    Martens, Uwe M.
    Thuss-Patience, Peter
    Egger, Matthias
    Block, Andreas
    Heinemann, Volker
    Illerhaus, Gerald
    Moehler, Markus
    Schenk, Michael
    Kullmann, Frank
    Behringer, Dirk M.
    Heike, Michael
    Pink, Daniel
    Teschendorf, Christian
    Loehr, Carmen
    Bernhard, Helga
    Schuch, Gunter
    Rethwisch, Volker
    von Weikersthal, Ludwig Fischer
    Hartmann, Joerg T.
    Kneba, Michael
    Daum, Severin
    Schulmann, Karsten
    Weniger, Joerg
    Belle, Sebastian
    Gaiser, Timo
    Oduncu, Fuat S.
    Guentner, Martina
    Hozaeel, Wael
    Reichart, Alexander
    LANCET, 2019, 393 (10184): : 1948 - 1957
  • [27] Claudin 18.2-targeting antibody-drug conjugate CMG901 in patients with advanced gastric or gastro-oesophageal junction cancer (KYM901): a multicentre, open-label single-arm, phase 1 trial
    Ruan, Dan-Yun
    Liu, Fu-Rong
    Wei, Xiao-Li
    Luo, Su-Xia
    Zhuang, Zhi-Xiang
    Wang, Zhen-Ning
    Liu, Fu-Nan
    Zhang, Yan-Qiao
    Yang, Jian-Wei
    Chen, Zhen-Dong
    Wang, Yong-Sheng
    Wang, Jun-Ye
    Liang, Xiao-Hua
    Wu, Xiao-Jie
    Zheng, Yu-Long
    Liu, Jian
    Shi, Xi
    Kumar, Rakesh
    Liu, Wei
    Chen, Bo
    Zhang, Dong-Sheng
    Xu, Rui-Hua
    LANCET ONCOLOGY, 2025, 26 (02): : 227 - 238
  • [28] Anti-PD-1 antibody SHR-1210 plus apatinib for metastatic colorectal cancer: a prospective, single-arm, open-label, phase II trial
    Ren, Chao
    Mai, Zong-Jiong
    Jin, Ying
    He, Ming-Ming
    Wang, Zhi-Qiang
    Luo, Hui-Yan
    Zhang, Dong-Sheng
    Wu, Chen-Yi
    Wang, Feng
    Xu, Rui-Hua
    AMERICAN JOURNAL OF CANCER RESEARCH, 2020, 10 (09): : 2946 - +
  • [29] Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE) final report of a randomised, open-label, phase 3 trial
    Zhang, Xiaotian
    Liang, Han
    Li, Ziyu
    Xue, Yingwei
    Wang, Yanong
    Zhou, Zhiwei
    Yu, Jiren
    Bu, Zhaode
    Chen, Lin
    Du, Yian
    Wang, Xinbao
    Wu, Aiwen
    Li, Guoli
    Su, Xiangqian
    Xiao, Gang
    Cui, Ming
    Wu, Dan
    Chen, Li
    Wu, Xiaojiang
    Zhou, Yanbing
    Zhang, Lianhai
    Dang, Chengxue
    He, Yulong
    Zhang, Zhongtao
    Sun, Yihong
    Li, Yong
    Chen, Huanqiu
    Bai, Yuxian
    Wang, Yakun
    Yu, Peiwu
    Zhu, Guanbao
    Suo, Jian
    Jia, Baoqing
    Li, Leping
    Huang, Changming
    Li, Fei
    Ye, Yingjiang
    Xu, Huimian
    Wang, Xin
    Yuan, Yannan
    Jianyu, E.
    Ying, Xiangji
    Yao, Chen
    Shen, Lin
    Ji, Jiafu
    LANCET ONCOLOGY, 2025, 26 (03): : 312 - 319
  • [30] Induction therapy with PD-1 antibody combined with platinum-based doublet chemotherapy for locally-advanced non-small cell lung cancer: A randomised controlled, open-label, phase 2 trial
    Wang, Suyu
    Zhang, Peng
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345